Anti-cancer therapeutic compounds

Details Anti-cancer therapeutic compounds Anti-cancer therapeutic compounds

2007-10-23

2007-10-23

Hui, San-Ming (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

10002145

ABSTRACT:
A treatment for cancer, and in particular, of therapeutic compounds which block the ability of cytokines and chemokines to promote metastasis of malignant cells. The therapeutic compound comprises a carboxylated and/or sulfated oligosaccharide, preferably in a substantially purified form, which is a heparin or heparan-sulfate derived saccharide compound. In one embodiment of the present invention, the carbohydrate or oligosaccharide has a molecular weight of no more than about 3000 daltons, preferably lying in the range of about 400 to about 2000 daltons, most preferably between about 400 and about 1100 daltons. Generally, substances of the present invention inhibit tumor cell migration, as determined by biological assays, and comprise molecules of various sugar units of which the basic unit of activity is associated with a disaccharide. However, larger oligosaccharide chains of up to about 10 sugar units, containing the basic disaccharide unit of activity can also function to inhibit such activity.

REFERENCES:
patent: 1950100 (1934-06-01), Crandall
patent: 4401662 (1983-08-01), Lormeau et al.
patent: 4446314 (1984-05-01), Jordan
patent: 4468385 (1984-08-01), Callahan et al.
patent: 4539398 (1985-09-01), Rosenberg
patent: 4607025 (1986-08-01), Petitou et al.
patent: 4727063 (1988-02-01), Naggi et al.
patent: 4774231 (1988-09-01), Petitou et al.
patent: 4801583 (1989-01-01), Petitou et al.
patent: 4818816 (1989-04-01), Petitou et al.
patent: 4882318 (1989-11-01), Vlodavsky et al.
patent: 4889808 (1989-12-01), Rappaport
patent: 4933326 (1990-06-01), Bianchini et al.
patent: 4943630 (1990-07-01), Jacquinet et al.
patent: 4973580 (1990-11-01), Mascellani et al.
patent: 4981955 (1991-01-01), Lopez
patent: 4987223 (1991-01-01), Choay et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5010063 (1991-04-01), Piani et al.
patent: 5034520 (1991-07-01), Lormeau et al.
patent: 5474987 (1995-12-01), Cohen et al.
patent: 5580858 (1996-12-01), Ippolito et al.
patent: 5686431 (1997-11-01), Cohen et al.
patent: 5861382 (1999-01-01), Cohen et al.
patent: 5908837 (1999-06-01), Cohen et al.
patent: 6020323 (2000-02-01), Cohen et al.
patent: 6750207 (2004-06-01), Cohen et al.
patent: 2004/0198697 (2004-10-01), Cohen et al.
patent: 0114589 (1984-01-01), None
patent: 0375976 (1990-04-01), None
patent: 0394971 (1990-10-01), None
patent: 0669827 (2001-05-01), None
patent: PCT WO 88/05301 (1988-07-01), None
patent: PCT WO 89/05645 (1989-06-01), None
patent: PCT WO 90/03791 (1990-04-01), None
patent: PCT WO 94/11006 (1994-05-01), None
patent: PCT WO 03/047501 (2003-06-01), None
Timar et al., Invasion Metastasis, 1990;10:301-305.
Vlodavsky et al., Adv. Exp. Med. Biol., 992;13:317-327.
Oligossacharide in Chemical Dictionary, 5th ed., McGraw-Hill, 1987.
Timar et al. “Interactions of Exogenous Heparan Sulfate with Tumor Cells of Different Metastatic Phenotype”, Invasion Metastasis, 10: 301-315, 1990.
Murdoch et al. “Chemokine Receptors and Their Role in Inflammation and Infectious Diseases”, Blood, 95(10): 3032-3043, 2000.
Oberlin et al. “The CXC Chemokine SDF-1 Is the Ligand for LESTR/Fusin and Prevents Infection by T-Cell-Line-Adapted HIV-1”, Nature, 382: 833-835, 1996.
Nagasawa et al. “Defects of B-Cell Lymphopoiesis and Bone-Marrow Myelopoiesis in Mice Lacking the CXC Chemokine PBSF/SDF-1”, Nature, 382: 635-638, 1996.
McGrath et al. “Embryonic Expression and Function of the Chemokine SDF-1 and Its Receptor, CXCR4”, Developmental Biology, 213: 442-456, 1999.
Ponomaryov et al. “Induction of the Chemokine Stromal-Derived Factor-1 Following DNA Damage Improves Human Stem Cell Function”, The Journal of Clinical Investigation, 106(11): 1331-1339, 2000.
Gonzalo et al. “Critical Involvement of the Chemotactic Axis CXCR4/Stromal Cell-Derived Factor-1α in the Inflammatory Component of Allergic Airway Disease”, The Journal of Immunology, 165: 499-508, 2000.
Peled et al. “The Chemokine SDF-1 Stimulates Integrin-Mediated Arrest of CD34+ Cells on Vascular Endothelium Under Shear Flow”, The Journal of Clinical Investigation, 104(9): 1199-1211, 1999.
Peled et al. “Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4”, Science, 283: 845-848, 1999.
Sawada et al. “Disturbed CD4+ T Cell Homeostasis and In Vitro HIV-1 Susceptibily in Transgenic Mice Expressing T Cell Line-Tropic HIV-1 Receptors”, Journal of Experimental Medicine, 187(9): 1439-1449, 1998.
Aiuti et al. “The Chemokine SDF-1 Is A Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides A New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood”, Journal of Experimental Medicine, 185(1): 111-120, 1997.
Peled et al. “The Chemokine SDF-1 Activates the Integrins LFA-1, VLA-4, and VLA-5 on Immature Human CD34+ Cells: Role in Transendothelial/Stromal Migration and Engraftment of NOD/SCID Mice”, Blood, 95(11): 3289-3296, 2000.
Edinger et al. “Noninvasive Assessment of Tumor Cell Proliferation in Animal Models”, Neoplasia, 1(4): 303-310, 1999.
Contag et al. “Bioluminescent Indicators in Living Mammals”, Nature Medicine, 4(2): 245-247, 1998.
Condiotti et al. “Effect of Interleukin-12 on Antitumor Activity of Human Umbilical Cord Blood and Bone Marrow Cytotoxic Cells”, Experimental Hematology, 26: 571-579, 1998.
Chowers et al. “Disaccharides Derived From Heparin or Heparan Sulfate Regulate IL-8 and IL-1β Secretion by Intestinal Epithelial Cells”, Gastroenterology, 120: 449-459, 2001.
Goodman et al. “Anticoagulant, Thrombolytic, and Antiplatelet Drugs”, The Pharmacological Basis of Theapeutics, II(Chap.55): 1312-1315, 1992.
Vlodavsky et al. “Modulation of Neovascularization and Metastasis by Species of Heparin”, Adv. Exp. Med. Biol., 13: 317-327, 1992.
Hershkoviz et al. “Disaccharides Generated From Heparan Sulphate or Heparin Modulate Chemokine-Induced T-Cell Adhesion to Extracellular Matrix”, Immunology, 99: 87-93, 2000.
Lider et al. “A Disaccharide That Inhibits Tumor Necrosis Factor α Is Formed From the Extracellular Matrix by the Enzyme Heparanase”, Proc. Natl. Acad. Sci. USA, 92: 5037-5041, 1995.
Cahalon et al. “Heparin Disaccharides Inhibit Tumor Necrosis Factor-α Production by Macrophages and Arrest Immune Inflammation in Rodents”, International Immunology, 9(10): 1517-1522, 1997.
Horvath et al. “Low Dose Heparin and Early Kidney Transplant Function”, Australian and New Zealand Journal of Medicine, 5: 537-539, 1975.
Kariya et al. “Preparation of Unsaturated Disaccharides by Eliminative Cleavage of Heparin and Heparan Sulfate With Heparitinases”, Comp. Biochem. Physiol., 103B: 473-479, 1992.
Lider et al. “Inhibition of T Lymphocyte Heparanase by Heparin Prevents T Cell Migration and T Cell-Mediated Immunity”, European Journal of Immunology, 20: 493-499, 1990.
Lider et al. “Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparins”, The Journal of Clinical Investigation, 83: 752-756, 1989.
Neparstek et al. “Activated T Lymphocytes Produce A Matrix-Degrading Heparan Sulphate Endoglycosidase”, Nature, 310: 241-244, 1984.
Psuja “Affinity of Binding of Radiolabeled (125 I) Heparin and Low Molecular Weight Heparin Fraction CY 222 to Endothelium in Culture”, Folia Haematol., 114(3): 429-436, 1987.
Toivonen et al. “Rat Adjuvant Arthritis as A Model to Test Potential Antirheumatic Agents”, Meth. and Find. Exptl. Clin. Pharmacol., 4(6): 359-363, 1982.
Asselot et al. “Heparin Fragments Regulate Collagen Phenotype and Fibronectin Synthesis in the Skin of Genetically Diabetic Mice”, Biochemical Pharmacology, 38(6): 895-899, 1989.
Asselot-Chapel et al. “Biosyntheses of Interstitial Colla

Affiliated with

Also associated with

Rating

Anti-cancer therapeutic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer therapeutic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer therapeutic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3899652